Quantcast

Latest Neuroendocrine tumor Stories

2011-08-09 05:00:00

THE WOODLANDS, Texas, Aug. 9, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract. It is characterized by...

2011-08-02 00:00:31

A targeted and personalized medicine approach to lung cancer. Somerville, MA (PRWEB) August 01, 2011 Andarix Pharmaceuticals, a clinical stage company, announces the appointment of leading clinical oncology experts to its clinical advisory board. The Advisors will work with the company to guide development of the company's lead candidate, a novel targeted therapy for lung and other cancers. Newly appointed Advisory board members have broad expertise in clinical research and treatment of...

2011-06-30 13:46:02

A new treatment option may soon be available for children with neuroblastoma according to research published in the July issue of The Journal of Nuclear Medicine. The study tested the principle that combined positron emission tomography and X-ray computed tomography (PET/CT) may be used to select children with primary refractory or relapsed high-risk neuroblastoma for treatment with a molecular radiotherapy known as 177Lu-DOTATATE. This therapeutic option was found to be viable option for...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related